A role for type 1α corticotropin-releasing hormone receptors in mediating local changes in chronically inflamed tissue

American Journal of Pathology

Volumn 170, Issue 3, 2007, Pages 1121-1133

  Ralph, Jennifer A ^a   Zocco, Davide ^a   Bresnihan, Barry ^b   FitzGerald, Oliver ^b   McEvoy, Alice N ^a   Murphy, Evelyn P ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING HORMONE RECEPTOR 1ALPHA; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HISTAMINE; HISTAMINE RECEPTOR; HISTAMINE RECEPTOR TYPE 1; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NURR1 NUCLEAR RECEPTOR; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNOVIUM; CELL CULTURE; CHRONIC DISEASE; CONFOCAL MICROSCOPY; CYTOLOGY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; NORTHERN BLOTTING; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

ANTIGENS, CD31; ARTHRITIS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CELLS, CULTURED; CHRONIC DISEASE; CREB-BINDING PROTEIN; DNA-BINDING PROTEINS; E-SELECTIN; ENDOTHELIAL CELLS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HISTAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROSCOPY, CONFOCAL; NF-KAPPA B; NITRIC OXIDE; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247890246     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.061000     Document Type: Article

References (60)

1. Karalis KP, Kontopoulos E, Muglia LJ, Majzoub JA: Corticotropin-releasing hormone deficiency unmasks the proinflammatory effect of epinephrine. Proc Natl Acad Sci USA 1999, 96:7093-7097 [erratum 2000, 97:3782]
2. Fife MS, Fisher SA, John S, Worthington J, Shah CJ, Ollier WE, Panayi GS, Lewis CM, Lanchbury JS: Multipoint linkage analysis of a candidate gene locus in rheumatoid arthritis demonstrates significant evidence of linkage and association with the corticotropin-releasing hormone genomic region. Arthritis Rheum 2000, 43:1673-1678
3. Fife M, Steer S, Fisher S, Newton J, McKay K, Worthington J, Shah C, Polley A, Rosenthal A, Ollier W, Lewis C, Wordsworth P, Lanchbury J: Association of familial and sporadic rheumatoid arthritis with a single corticotropin-releasing hormone genomic region (8q12.3) haplotype. Arthritis Rheum 2002, 46:75-82
4. Crofford LJ, Sano H, Karalis K, Friedman TC, Epps HR, Remmers EF, Mathern P, Chrousos GP, Wilder RL: Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 1993, 151:1587-1596
5. Murphy EP, McEvoy A, Conneely OM, Bresnihan B, FitzGerald O: Involvement of the nuclear orphan receptor NURR1 in the regulation of corticotropin- releasing hormone expression and actions in human inflammatory arthritis. Arthritis Rheum 2001, 44:782-793
6. McEvoy A, Bresnihan B, FitzGerald O, Murphy E: Corticotropin releasing hormone (CRH) signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1α CRH receptor. Arthritis Rheum 2001, 44:1761-1767
7. McEvoy AN, Bresnihan B, Fitzgerald O, Murphy EP: Corticotropin-releasing hormone signaling in synovial tissue vascular endothelium is mediated through the cAMP/CREB pathway. Ann NY Acad Sci 2002, 966:119-130
8. Webster E, Barrientos RM, Contoreggi C, Isaac MG, Ligier S, Gabry KE, Chrousos GP, McCarthy EF, Rice KC, Gold PW, Sternberg EM: Corticotropin- releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. J Rheumatol 2002, 29:1252-1261
9. Tetlow LC, Harper N, Dunningham T, Morris MA, Bertfield H, Woolley DE: Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis 1998, 57:25-32
10. Woolley DE, Tetlow LC: Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res 2000, 2:65-74
11. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, Chrousos G: Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998, 139:403-413
12. Koch AE: Angiogenesis: implications for rheumatoid arthritis (Review). Arthritis Rheum 1998, 41:951-962
13. Szekanecz ZKA: Cell-cell interactions in synovitis: endothelial cells and immune cell migration. Arthritis Res 2000, 2:368-373
14. Tarrant TK, Patel DD: Chemokines and leukocyte trafficking in rheumatoid arthritis. Pathophysiology 2006, 13:1-14
15. Middleton J, Americh L, Gayon R, Julien D, Aguilar L, Amalric F, Girard JP: Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther 2004, 6:60-72
16. Szekanecz Z, Koch AE: Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Curr Opin Pharmacol 2004, 4:423-428
17. Koch AE: Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005, 52:710-721
18. McEvoy AN, Bresnihan B, FitzGerald O, Murphy EP: Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue. Arthritis Rheum 2004, 50:1132-1145
19. Takeba Y, Suzuki N, Wakisaka S, Takeno M, Kaneko A, Asai T, Sakane T: Involvement of cAMP responsive element binding protein (CREB) in the synovial cell hyperfunction in patients with rheumatoid arthritis. Clin Exp Rheumatol 2000, 18:47-55
20. McEvoy AN, Murphy EA, Ponnio T, Conneely OM, Bresnihan B, FitzGerald O, Murphy EP: Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5′-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. J Immunol 2002, 168:2979-2987
21. Ralph JA, McEvoy AN, Kane D, Bresnihan B, FitzGerald O, Murphy EP: Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. J Immunol 2005, 175:555-565
22. Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P: Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem 2005, 280:29256-29262
23. Pei L, Castrillo A, Tontonoz P: Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol Endocrinol 2006, 20:786-794
24. Holla VR, Mann JR, Shi Q, DuBois RN: Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 2006, 281:2676-2682
25. Zeng H, Qin L, Zhao D, Tan X, Manseau EJ, Van Hoang M, Senger DR, Brown LF, Nagy JA, Dvorak HF: Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. J Exp Med 2006, 203:719-729
26. Xu Y, Swerlick RA, Sepp N, Bosse D, Ades EW, Lawley TJ: Characterization of expression and modulation of cell adhesion molecules on an immortalized human dermal microvascular endothelial cell line (HMEC-1). J Invest Dermatol 1994, 102:833-837
27. Lammi J, Huppunen J, Aarnisalo P: Regulation of the osteopontin gene by the orphan nuclear receptor Nurr1 in osteoblasts. Mol Endocrinol 2004, 18:1546-1557
28. Chen R, Lewis KA, Perrin MH, Vale WW: Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 1993, 90:8967-8971
29. Volin MV, Szekanecz Z, Halloran MM, Woods JM, Magua J, Damergis JA Jr, Haines KG III, Crocker PR, Koch AE: PECAM-1 and leukosialin (CD43) expression correlate with heightened inflammation in rat adjuvant-induced arthritis. Exp Mol Pathol 1999, 66:211-219
30. Elewaut D, De Keyser F, De Wever N, Baeten D, Van Damme N, Verbruggen G, Cuvelier C, Veys EM: A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers. Ann Rheum Dis 1998, 57:480-486
31. Storgard C, Stupack D, Jonczyk A, Cheresh D: Decreased angiogenesis and arthritic disease in rabbits treated with avb3 antagonist. J Clin Invest 1999, 103:47-54
32. Murphy EP, Conneely OM: Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors. Mol Endocrinol 1997, 11:39-47
33. Rossant CJ, Pinnock RD, Hughes J, Hall MD, McNulty S: Corticotropin-releasing factor type-1 and type-2a receptors regulate phosphorylation of calcium/cyclic adenosine 3′, 5′-monophosphate response element-binding protein and activation of p42/44 mitogen-activated protein kinase. Endocrinology 1999, 140:1525-1536
34. Grammatopoulos DK, Chrousos GP: Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 2002, 13:436-444
35. Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N: Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 1995, 96:2357-2363
36. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998, 41:1258-1265
37. Aggelidou E, Hillhouse EW, Grammatopoulos DK: Up-regulation of nitric oxide synthase and modulation of the guanylate cyclase activity by corticotropin-releasing hormone but not urocortin II or urocortin III in cultured human pregnant myometrial cells. Proc Natl Acad Sci USA 2002, 99:3300-3305
38. Karteris E, Vatish M, Hillhouse EW, Grammatopoulos DK: Preeclampsia is associated with impaired regulation of the placental nitric oxide-cyclic guanosine monophosphate pathway by corticotropin-releasing hormone (CRH) and CRH-related peptides. J Clin Endocrinol Metab 2005, 90:3680-3687
39. Crofford LJ, Sano H, Karalis K, Webster EL, Goldmuntz EA, Chrousos GP, Wilder RL: Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest 1992, 90:2555-2564
40. Tak P, Bresnihan B: The pathogenesis and prevention of joint damage in rheumatoid arthritis. Arthritis Rheum 2000, 43:2619-2633
41. Arbiser JL, Karalis K, Viswanathan A, Koike C, Anand-Apte B, Flynn E, Zetter B, Majzoub JA: Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol 1999, 113:838-842
42. Kriegsmann J, Keyszer GM, Geiler T, Lagoo AS, Lagoo-Deenadayalan S, Gay RE, Gay S: Expression of E-selectin messenger RNA and protein in rheumatoid arthritis. Arthritis Rheum 1995, 38:750-754
43. Proudman SM, Cleland LG, Mayrhofer G: Effects of tumor necrosis factor-alpha, interleukin 1beta, and activated peripheral blood mononuclear cells on the expression of adhesion molecules and recruitment of leukocytes in rheumatoid synovial xenografts in SCID mice. J Rheumatol 1999, 26:1877-1889
44. Mamdouh Z, Chen X, Pierini LM, Maxfield FR, Muller WA: Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 2003, 421:748-753
45. Akdis CA, Blaser K: Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003, 112:15-22
46. Asako H, Kurose I, Wolf R, DeFrees S, Zheng ZL, Phillips ML, Paulson JC, Granger DN: Role of H1 receptors and P-selectin in histamine-induced leukocyte rolling and adhesion in postcapillary venules. J Clin Invest 1994, 93:1508-1515
47. Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R: Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001, 60:1133-1142
48. Parham KL, Zervou S, Karteris E, Catalano RD, Old RW, Hillhouse EW: Promoter analysis of human corticotropin-releasing factor (CRF) type 1 receptor and regulation by CRF and urocortin. Endocrinology 2004, 145:3971-3983
49. Bonta PI, van Tiel CM, Vos M, Pols TW, van Thienen JV, Ferreira V, Arkenbout EK, Seppen J, Spek CA, van der Poll T, Pannekoek H, de Vries CJ: Nuclear Receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler Thromb Vasc Biol 2006, 26:2288
50. Wakisaka S, Suzuki N, Takeba Y, Nagafuchi H, Saito N, Hashimoto H, Tomita T, Ochi T, Sakane T: Involvement of simultaneous multiple transcription factor expression, including cAMP responsive element binding protein and OCT-1 for synovial cell outgrowth in patients with rheumatoid arthritis. Ann Rheum Dis 1998, 57:487-494
51. Firestein GS, Manning AM: Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999, 42:609-621
52. Tak PP, Firestein GS: NF-kB: a key role in inflammatory diseases. J Clin Invest 2001, 107:7-11
53. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS, Makarov SS: NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998, 95:13859-13864
54. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP: Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 2000, 105:1799-1806
55. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Dobner P, Theoharides TC: Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006, 103:7759-7764
56. Crompton R, Clifton VL, Bisits AT, Read MA, Smith R, Wright IM: Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. J Clin Endocrinol Metab 2003, 88:5427-5432
57. Clifton VL, Read MA, Leitch IM, Boura AL, Robinson PJ, Smith R: Corticotropin-releasing hormone-induced vasodilatation in the human fetal placental circulation. J Clin Endocrinol Metab 1994, 79:666-669
58. Clifton VL, Read MA, Leitch IM, Giles WB, Boura AL, Robinson PJ, Smith R: Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3′,5′-monophosphate-mediated pathway. J Clin Endocrinol Metab 1995, 80:2888-2893
59. Jain V, Vedernikov YP, Saade GR, Chwalisz K, Garfield RE: The relaxation responses to corticotropin-releasing factor in rat aorta are endothelium dependent and gestationally regulated. Am J Obstet Gynecol 1997, 176:234-240
60. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL, Theoharides TC: Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 2005, 174:7665-7675